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Dear Sir,
Atherosclerosis is one of the most significant
yet unresolved problems in patients on regu-
lar hemodialysis (HD) with major impact on
morbidity and mortality in patients with
end-stage renal disease. A number of risk
factors associated with the development of
atherosclerosis in HD patients have been
identified, such as hyperlipidemia, hyper-
tension, diabetes, smoking and obesity [1].
There is growing evidence that atherosclero-
sis may – at least in part – result from
autoimmune processes, in which the family
of heat-shock proteins (HSP) may be in-
volved [2]. HSPs are a family of about two
dozen proteins which show highly homolo-
gous sequences between bacterial and mam-
malian species. They are induced during
chronic inflammation and other forms of
physiological stress. Experimental evidence
has shown that expression of HSP 60 on
endothelial cells triggers early inflammatory
atherosclerotic changes [3]. Furthermore,
immunisation of normocholesterolemic rab-
bits with a mycobacterial 65-kD HSP
(mHSP 65) induced typical atherosclerotic
lesions [2]. Crossreactivity of serum anti-
bodies against mHSP 65 with the human 60-
kD homologue present in high levels in ath-
erosclerotic lesions was demonstrated by
immunoblotting and immunofluorescence
techniques [4]. In a series of 27 human sub-
jects HSP 60 could be detected on endothe-
lium, smooth muscle cells and/or mononu-
clear cells of carotid and aortic specimens
with atherosclerotic lesions. No expression
of stress protein was detectable on control
specimens with normal intima [5].
In the present series we studied antibody
titers against mHSP 65 in patients on regular
hemodialysis (HD) (table 1). In total, 77 pa-
tients were included in the study (27 females,
50 males; mean age 59 B 12 years). The
major causes for end-stage renal disease were
chronic glomerulonephritis, diabetic ne-
phropathy and interstitial nephritis. Of the
77 patients 29 (6 females, 23 males; mean
age 61 B 12 years) showed typical manifes-
tations of vascular disease as defined by car-
diac ischemia and/or peripheral vascular dis-
ease. All 29 patients had typical clinical
symptoms and angiography was performed
to confirm the diagnosis. The remaining 48
patients (21 females, 27 males; mean age 57
B 13 years) did not show symptoms of sig-
nificant vascular disease. As a control, sera
were obtained from healthy subjects (medi-
cal students and laboratory staff, n = 90, 48
females, 42 males, mean age 32 B 12 years).
Purified recombinant (r)mHSP 65 has been
kindly provided by Dr. Jan van Embden
from the WHO IMMTUB/IMMLEP Bank.
The microtiter plates were coated with
mHSP 65 overnight at 4°C. After a washing
step, the wells were blocked with non-fatty
dry milk powder (Merck) in PBS and after
washing incubated with diluted patient sera.
After extensive washing the plates were incu-
bated with peroxidase-conjugated rabbit an-
tihuman IgG antiserum. The plates were
washed again and developed by addition of
substrate. The absorbance was measured in
an ELISA reader at 405 nm. In each assay
one positive serum was included as a posi-
Table 1. Serum anti-HSP 65 antibody titers of indicated groups of patients on regular
hemodialysis (OD ratio)
Healthy
controls
All HD
patients
HD patients
with AS
HD patients
without AS
90 77 29 48
Mean age, years 32B12 59B12 61B12 57B13
Mean time on HD, months 58 42 68
Means 0.0475 0.156 0.227 0.116
+ SEM 0.004 0.137 0.144 0.116
Significance1 p ! 0.05* p ! 0.01 p 1 0.05
HD = Hemodialysis; AS = atherosclerosis.
* Kruskal-Wallis test.
1 Compared to healthy controls.
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tive control and 3 negative sera as negative
controls. Arbitrary units were calculated for
accurate interassay comparison using the
formula: OD ratio = OD sample/OD posi-
tive control.
In our study increased circulating anti-
bodies to rmHSP 65 were detectable in only
2 of 90 healthy donors. The titers of rmHSP
65 antibodies of all HD patients were signifi-
cantly elevated (OD ratio 0.156, p ! 0.05)
(table 1). The analysis of the two subgroups
of HD patients with or without manifesta-
tions of vascular disease as defined by the
criteria above, showed no significant differ-
ence of rmHSP 65 antibody titers between
healthy controls and HD patients without
vascular disease (OD ratio 0.116, p 1 0.05).
On the other hand, HD patients with vascu-
lar disease had clearly elevated antibody ti-
ters to rmHSP 65 as compared to healthy
controls (OD ratio 0.227, p ! 0.01). The
comparison of the two subgroups of HD
patients revealed the most striking differ-
ence in antibody titers to rmHSP 65 (OD
ratio 0.227 vs. 0.116, p ! 0.001).
The present study shows a correlation
between serum anti-HSP 65 antibody titers
and vascular events in end-stage renal dis-
ease. As HD patients with no major underly-
ing vascular disease do not differ from the
normal population in that respect, the inten-
sity and duration of hemodialysis treatment
by itself does not seem to be responsible for
increased anti-HSP 65 antibodies. High se-
rum antibodies to HSP 65 have been found
in patients with symptomatic carotid athero-
sclerosis [1] or in patients with ischemic vas-
culitis [6]. None of these patients suffered
end-stage renal disease. Whether or not se-
rum antibodies increase with age or are the
manifestations of atherosclerosis in elderly
subjects remains controversial. Canadian in-
vestigators have attributed elevated serum
anti-HSP 65 antibodies to age in patients
with thrombotic stroke or transient ischemic
attacks, but not to the number of cerebrovas-
cular events [7]. Looking at our data, we can-
not support this observation in our patient
group. Although the age-related increase of
serum anti-HSP 65 antibodies as well as ath-
erosclerosis is well known [1], HD patients
with vascular disease were only slightly older
than those without vascular damage. In con-
clusion, our data provide further evidence
for the hypothesis of an autoimmune induc-
tion of early inflammatory arteriosclerotic
changes since HD patients with well-defined
vascular lesions have high titers of anti-HSP
65 antibodies independent of age and meth-
odology. Further studies are necessary to de-
termine whether antibodies to HSP 65 are of
diagnostic and prognostic value in patients
on chronic hemodialysis.
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